Clinical prognostic factors and survival study of primary thyroid lymphoma:a single-center retrospective study
ZHAO Hai-xin
GENG Zu-shi
LU Xiu-bo
Abstract：Objective To analyze the clinical features of primary thyroid lymphoma(PTL)and the related factors of pri-mary thyroid diffuse large B cell lymphoma(PTDLBCL)affecting overall survival(OS)and progression-free survival(PFS).Methods The clinical data of 74 patients with PTL who were diagnosed with Ann Arbor stage ⅠE-ⅡE in the First Affiliated Hospital of Zhengzhou University from 2011 to 2022 were retrospectively collected.A descriptive analysis was carried out on the clinical features,treatment,and follow-up.54 patients with PTDLBCL were subjected to prognos-tic univariate analysis and multivariate analysis.Kaplan-Meier method and Log-rank test were used for univariate analy-sis and multivariate analysis using the Cox proportional hazards regression model.Results The median follow-up time of 74 PTL patients was 26 months(range,1-117 months),and the 1-year,3-year,and 5-year OS were 85.0％,78.4％,and 75.6％;the 1-year,3-year,and 5-year PFS were 76.5％,71.7％,and 63.1％.Multivariate analysis shows that the use of anti-CD20 monoclonal antibody(P=0.020)is a protective factor for OS in patients with PTDLBCL;chemotherapy-based combined treatment with surgery or radiotherapy(P=0.046),and treatment with anti-CD20 monoclonal antibody(P=0.003)are the protective factors for PFS.Conclusion The main pathological type of PTL is DLBCL.For PTDLBCL patients,therapy with anti-CD20 monoclonal antibody is more beneficial to improve the OS and PFS,comprehensive treatment with chemotherapy as the main treatment can help prolong the PFS.
Keywords：primary thyroid lymphomadiffuse large B-cell lymphomaprognosisprogression-free survival
Publication Date：2023-12-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 1422-1428 )